An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer

Title
An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer
Authors
Keywords
Chemotherapy, Cisplatin, Cost-effectiveness, Dose-dense (dd)MVAC, Gemcitabine, Muscle-invasive bladder cancer, Neoadjuvant, Resource utilization
Publisher
Elsevier BV
Online
2021-06-20
DOI
10.1016/j.urolonc.2021.04.032

Ask authors/readers for more resources

Reprint

Contact the author

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Search

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started